Product Images Lurasidone Hydrochloride

This text is not readable and the description cannot be generated.*

This text provides information on the impact of certain drugs on the pharmacokinetics of Lurasidone. The drugs are categorized based on their ability to inhibit or induce CYP3A4, a liver enzyme that metabolizes many medications. The text reports the fold change and 90% CI for Lurasidone's Cmax and AUC when co-administered with the interacting drug. Ketoconazole, a strong CYP3A4 inhibitor, increased Lurasidone's Cmax and AUC. Diltiazem, a moderate CYP3A4 inhibitor, increased Lurasidone's Cmax and AUC to a lesser extent. Rifampin, a strong CYP3A4 inducer, decreased Lurasidone's Cmax and AUC. Finally, Lithium did not change Lurasidone's Cmax or AUC.*

This appears to be a table containing information about the fold change and 90% confidence interval for various drugs and their substrates. The top row contains column headers indicating the drugs or substrates being studied, and the units being measured (e.g. mg, Cmax). The row below the headers appears to show the fold change and confidence intervals for each substrate when interacting with the given drug. The last row shows the change relative to the interactive drug alone. However, more context is needed to fully understand what this table is analyzing.*